

## S 4338

### Increasing Transparency in Generic Drug Applications Act

**Congress:** 117 (2021–2023, Ended)

**Chamber:** Senate

**Policy Area:** Health

**Introduced:** May 26, 2022

**Current Status:** Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

**Latest Action:** Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (May 26, 2022)

**Official Text:** <https://www.congress.gov/bill/117th-congress/senate-bill/4338>

### Sponsor

**Name:** Sen. Hassan, Margaret Wood [D-NH]

**Party:** Democratic • **State:** NH • **Chamber:** Senate

### Cosponsors (1 total)

Cosponsor	Party / State	Role	Date Joined
Sen. Paul, Rand [R-KY]	R · KY		May 26, 2022

### Committee Activity

Committee	Chamber	Activity	Date
Health, Education, Labor, and Pensions Committee	Senate	Referred To	May 26, 2022

### Subjects & Policy Tags

#### Policy Area:

Health

### Related Bills

Bill	Relationship	Last Action
117 HR 7667	Related bill	Jun 9, 2022: Received in the Senate.
117 HR 7032	Related bill	Mar 10, 2022: Referred to the Subcommittee on Health.

### Summary (as of May 26, 2022)

#### Increasing Transparency in Generic Drug Applications Act

This bill requires the Food and Drug Administration to inform generic drug applicants, upon request or during review, whether the drug is qualitatively and quantitatively the same as the listed brand-name drug (and if not, the reasons why).

### Actions Timeline

- **May 26, 2022:** Introduced in Senate
- **May 26, 2022:** Read twice and referred to the Committee on Health, Education, Labor, and Pensions.